Emerging benefits of AT1 receptor antagonists with pleiotropic anti-inflammatory activity

American Journal of Hypertension

Volumn 24, Issue 7, 2011, Pages 739-

  Sernia, Conrad ^a   Brown, Lindsay ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SOUTHERN QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RAMIPRIL; ROSIGLITAZONE; TELMISARTAN; VALSARTAN;

ADIPOGENESIS; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BODY FAT; BONE DENSITY; DRUG MECHANISM; GLUCOSE HOMEOSTASIS; HEART PROTECTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NONHUMAN; NOTE; OBESITY; OSTEOPOROSIS; PLEIOTROPY; PRIORITY JOURNAL; RENAL PROTECTION;

EID: 79959347171     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1038/ajh.2011.61     Document Type: Note

References (6)

1. Khan MA, Imig JD. Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome. Am J Hypertens 2011; 24:816-821.
2. Iyer A, Fairlie DP, Prins JB, Hammock BD, Brown L. Inflammatory lipid mediators in adipocyte function and obesity. Nat Rev Endocrinol 2010; 6:71-82.
3. Bakris G. Are there effects of renin-angiotensin system antagonists beyond blood pressure control? Am J Cardiol 2010; 105:21A-29A.
4. Kojima S, Sakamoto T, Ogawa H, Kitagawa A, Matsui K, Shimomura H, Kimura K, Ogata Y, Sakaino N; Multicenter Study for Aggressive Lipid-lowering Strategy by HMG-CoA Reductase Inhibitors Investigators. Standard-dose statin therapy provides incremental clinical benefits in normocholesterolemic diabetic patients. Circ J 2010; 74:779-785.
5. de Kloet AD, Krause EG, Woods SC. The renin angiotensin system and the metabolic syndrome. Physiol Behav 2010; 100:525-534.
6. Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 2008; 19:129-137.